MedPath

Clinical Monitoring, MRI and Neuro-Ophthalmology of a Cohort of Patients With a Clinically Isolated Syndrome (CIS)

Conditions
Clinically Isolated Syndrome
Multiple Sclerosis
Registration Number
NCT03541226
Lead Sponsor
University Hospital, Lille
Brief Summary

The purpose of this study is to develop tools to detect, measure, monitor and predict axonal damage in the course of CIS and during Multiple sclerosis (MS), in order to be able to consider as early as possible an adaptation of the background treatment in patients with MS. patients with radiological criteria of poor long-term clinical course.

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
134
Inclusion Criteria
  • Any patient who has had a CIS of less than 4 months (+/- 15 days), with at least 1 inflammatory lesion on his initial brain MRI or with normal brain MRI associated with the presence of oligoclonal bands in the CSF,
Exclusion Criteria
  • Atypical CIS for a first relapse of multiple sclerosis (extensive myelitis, bilateral retrobulbar optic neuritis immediately)
  • CIS dating more than 4 months (+/- 15 days)
  • Corticotherapy in the last 4 weeks

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
severity of the disease defined by Expanded Disability Status Scale (EDSS) ≥ 2.0At 5 years
Secondary Outcome Measures
NameTimeMethod
Occurrence of a second pushAt 5 years
Occurrence of a handicap objectified by the Multiple Sclerosis Functional Composite(MSFC)At 5 years
variation of parameters measuring axonal pain / degeneration in MRIAt 5 years
variation of parameters measuring axonal pain / degeneration in OCTAt 5 years
Occurrence of progression of the EDSS (Expanded Disability Status Scale) scoreAt 5 years

The scale evaluated the pyramidal, cerebellar, sensory, visual and mental functions . These make it possible to obtain a quotation between 0 and 10. The walk is called "normal" from 0 to 3.5. The walk is hampered from 4 and impossible from 7.5. The coast of 10 corresponds to the death of the patient.

This measure differentiates two groups: severe EDSS and non-severe EDSS group,

Trial Locations

Locations (1)

Hôpital Roger Salengro, CHRU de Lille

🇫🇷

Lille, France

Hôpital Roger Salengro, CHRU de Lille
🇫🇷Lille, France
Patrick Vermersch, MD,PhD
Sub Investigator
Olivier Outteryck, MD
Principal Investigator

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.